Innovations in biosimilars: what health systems professionals should anticipate for 2026
Key insights
- Emerging Biosimilars Pipeline: A look at the biosimilars expected to launch in 2026 and their potential impact on therapeutic areas such as oncology, immunology, and more.
- Regulatory and Policy Developments: Updates on evolving FDA guidelines, interchangeability designations, and reimbursement models shaping biosimilar adoption.
- Operational Integration: Best practices for incorporating biosimilars into formularies, care pathways, and inventory management systems.
Speakers:
- Tasmina Hydery, PharmD, MBA, BCGP, FAMCP, Director, FormularyDecisions®
- Cynthia Thai, PharmD, Assistant Director, FormularyDecisions®
- Tatiana Tsybulevsky, MHA, CSM, CPM, Director of Commercial Solutions, Product Deployment, and Customer Success
Access the recording
Cencora.com is providing automated translations to assist in reading the website in languages other than English. For these translations, reasonable efforts have been made to provide an accurate translation, however, no automated translation is perfect nor is it intended to replace human translators. These translations are provided as a service to users of Cencora.com and are provided "as is." No warranty of any kind, either expressed or implied, is made as to the accuracy, reliability, or correctness of any of these translations made from English into any other language. Some content (such as images, videos, Flash, etc.) may not be accurately translated due to the limitations of the translation software.
Any discrepancies or differences created in translating this content from English into another language are not binding and have no legal effect for compliance, enforcement, or any other purpose. If any errors are identified, please contact us. If any questions arise related to the accuracy of the information contained in these translations, please refer to the English version of the page.